Navigation Links
Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
Date:10/20/2009

novative manufacturing solution. We appreciate having the opportunity and support to demonstrate the H1N1 vaccine's safety, immunogenicity and efficacy in Mexico and thereby help with ongoing pandemic response efforts. Similar to our previous announcements regarding our ongoing work in the countries of India and Spain, where we plan to establish in-border production, our planned clinical work in Mexico, if successful, could lead to rapid availability of the vaccine and advance Novavax's regional strategy to assist countries around the globe with such critical needs."

Virus-like particles (VLPs) mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs can be designed quickly to match individual viral strains and be produced efficiently using portable cell-culture technology. Novavax's VLP-based vaccine candidates are produced significantly more quickly than egg-based vaccines by using proprietary, portable, recombinant cell-culture technology.

The company will hold an investor conference call to discuss this clinical study at 9:00 a.m. Eastern Time on Tuesday, October 20, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of the company's senior management team. A question and answer session will follow. The dial-in number for the conference call is 1 (866) 206-5917 (International: 1 (703) 639-1106). A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.

A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning October 20, 2009 at
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
2. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
3. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
4. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
5. Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
6. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
7. NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
8. NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
9. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Synapse Biomedical Inc. ( www.synapsebiomedical.com ) ... the post-approval study of its NeuRx DPS® System ... meet the FDA enrollment requirement was implanted over ... The NeuRx DPS®, which is the only medical ... patients, is a humanitarian device that obtained approval ...
(Date:9/30/2014)... Sept. 30, 2014  eHealth, electronic access of ... access of this information, has become a major ... that has not translated into user-friendly, effective products. ... - http://photos.prnewswire.com/prnh/20140929/149123 For ... years developing MWD® Health Manager iEHR, a multilingual ...
(Date:9/30/2014)... Sept. 30, 2014 It is evident from the ... is not performing upto expectations due to the lack of ... with the intake of omega-3 fatty acids. Among omega-3 ingredient ... fish oil, attributed to the large vegetarian population in ... polyunsaturated fatty acid (PUFAs) ingredients is in growth stage of ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... The 2009 Frost & Sullivan European Medical ... the radiology applications market is conferred on Viatronix ... the diagnostic imaging space. , (Logo: ... Viatronix has shown dedication to both developing and ...
... PAC, a leading global provider of advanced analytical instruments ... of the ANTEK MultiTek(TM) testing system for the fast, ... and halides. Industries include BioFuels, Chemicals, Food & Beverage, ... , "MultiTek(TM) is the only instrument on the ...
Cached Medicine Technology:Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 2Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 3Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year 4New ANTEK MultiTek(TM) by PAC Provides Fast, All-in-One Testing for Sulfur, Nitrogen, Halides 2
(Date:9/30/2014)... 2014 issue of The FASEB Journal ... a simple blood test. This test, called the "lymphocyte genome ... than ever before, but it may eliminate the need for ... likely to develop cancer in the future. , "The ... peoples, lives," said Diana Anderson, a researcher involved in the ...
(Date:9/30/2014)... HealthDay Reporter MONDAY, Sept. 29, 2014 ... -- artificial valves, hip replacements, surgical mesh and the like ... after their approval by the U.S. Food and Drug Administration, ... prominent nonprofit groups and published online Sept. 29 in ... medical device testing on lax oversight by the FDA. ...
(Date:9/30/2014)... 30, 2014 Edward D. Buckingham, M.D., ... has been approved to be a director of a ... Reconstructive Surgery (AAFPRS) fellowship program. The announcement came last ... Florida. , The Educational and Research Foundation for the ... It represents the finest postgraduate program in the world ...
(Date:9/30/2014)... NC (PRWEB) September 30, 2014 ... and caring individuals, National Children’s Oral Health ... $150,000 in grants to non-profit clinical partners. ... Affiliate Network and deliver comprehensive educational, preventive ... , Recipients include:,     Just ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Herceptin is ... cancer called HER2-positive and should remain the standard of ... findings from a long-term clinical trial. HER2-positive breast ... of breast cancer, according to the Mayo Clinic. ... countries received either Herceptin (trastuzumab) or Tykerb (lapatinib) in ...
Breaking Medicine News(10 mins):Health News:New blood test determines whether you have or are likely to get cancer 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3
... from UCSF examining HIV among men who have sex with men ... that a third of gay-identified men are infected with HIV. ... HIV and the community of men who have sex with men ... reserved for black South Africans during apartheid. The researchers ...
... BANNOCKBURN, Ill., Aug. 31 Omron Healthcare has announced a ... The achievement is part of a journey that began 36 years ... , , What has followed since 1973? The ... around the world. From PC compatible units which allow you to ...
... , , , ... Ingelheim today announced that results from the RE-LY(R) (Randomized Evaluation of ... atrial fibrillation (AF) outcomes trial ever conducted(1) (18,113 patients in 44 ... European Society of Cardiology Congress and published online in the ...
... ... care and non-medical caregiver services in Northern California and Utah, has been approved for ... its Haven Healthcare office in Layton, Utah , ... Walnut Creek, CA (PRWEB) August 29, 2009 -- Professional ...
... ... show and discusses how to integrate the color blue for to calm the body and ... and and professional communications. , ... (Vocus) August 29, 2009 -- ColorAlchemy is featured on HeartandHome radio show (heartandhomehealing.com/upcoming_shows.htm) and discusses ...
... were affected, study found , FRIDAY, Aug. 28 (HealthDay ... may determine their odds for progressing to AIDS-linked dementia, ... are a common hallmark of HIV infection. But during ... Sacktor noted that people in areas where HIV subtypes ...
Cached Medicine News:Health News:High HIV infection rate among Soweto Township gays 2Health News:And the Beat Goes on 2Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 2Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 4Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 5Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 6Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 7Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 8Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 9Health News:Professional Healthcare Is Approved for Medicare Licenses at Additional Offices in California and Utah 2Health News:ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 2Health News:ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 3Health News:ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 4
Remote Controlled, Easy to Use,Vision Tester Designed for Screening Children Ages 3 and Older.,Excellent for Pediatric and School Markets....
Contrast Sensitivity is Recognized as a Valuable Tool for Measuring Functional Vision Loss Caused by Early Eye Disease. Distance Test S.W.C.T. 201: Size 27in x 37 in (68.58cm x 93.98cm),Can be Wal...
Vision Testing for Infants and Non-Verbal Patients,Using Preferential Looking....
Adult: Letter Acuity, Astigmatic Clock, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Medicine Products: